>유럽 CAR-T 세포 치료 시장, 제품별(자가 CAR-T 세포, 이종이식 CAR-T 세포), 구조(1세대 CAR-T 세포, 2세대 Car-T 세포, 3세대 CAR-T 세포, 4세대 CAR-T 세포), 표적 항원(고형 종양 항원, 혈액 악성 종양 항원, 기타), 브랜드(Yescarta, Kymriah, Tecartus, 기타), 치료적 적용(혈액 악성 종양, 췌장암, 유방암, 폐암, 위암, 다발성 골수종, 만성 림프구성 백혈병, 맨틀 세포 림프종, 모낭 림프종, 확산성 대형 B세포 림프종, 급성 림프모구 백혈병, 기타), 최종 사용자(병원, 전문 병원, 기타), 유통 채널(병원 약국, 기타), 국가 (독일, 영국, 프랑스, 이탈리아, 스페인, 네덜란드, 러시아, 스위스, 터키, 오스트리아, 노르웨이, 헝가리, 리투아니아, 아일랜드, 폴란드, 유럽의 나머지 지역) 2028년까지의 산업 동향 및 예측
시장 분석 및 통찰력 : 유럽 CAR-T 세포 치료 시장
CAR-T 세포 치료 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 29.4%의 CAGR로 성장하고 있으며 2028년까지 10,594.65백만 달러에 도달할 것으로 예상한다고 분석합니다. 암과 감염성 질환 치료를 위한 CAR-T 세포 치료 사용 증가가 CAR-T 세포 치료 시장 성장을 견인하고 있습니다.
CAR-T 세포 치료 또는 키메라 항원 수용체 T 세포는 다양한 암의 치료를 위한 면역 요법 으로 사용될 수 있는 인공 T 세포 수용체를 생산하기 위해 유전적으로 조작된 T 세포 입니다 . 키메라 항원 수용체는 실험실에서 조작되어 T 세포에 특정 단백질을 표적으로 삼는 새로운 능력을 제공한 수용체 단백질입니다.
면역 요법에 대한 인식이 높아짐에 따라 사람들은 여러 종류의 CAR-T 요법과 그 효과를 접하게 되었고, 따라서 CAR-T 세포 요법 치료 시장의 원동력이 되었습니다. 요법의 부작용으로 인해 일부 인구는 그러한 치료를 선택하지 못하게 되어 제품 가치에 영향을 미치고, 따라서 CAR-T 세포 요법 치료 시장 성장을 제한합니다. 파이프라인 제품의 존재는 시장 참여자가 끊임없이 혁신적인 의약품을 제조하고 있음을 시사하므로 CAR-T 세포 요법 치료 시장에 기회가 됩니다. 면역 요법의 승인 시간이 길어 제품 제조업체가 시장에서 잠재적 이익을 얻는 데 제한이 있고, 전체 시장 규모에 영향을 미치므로 CAR-T 세포 요법 치료 시장 성장에 도전이 됩니다.
The CAR-T cell therapy treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
Europe CAR-T Cell Therapy Treatment Market Scope and Market Size
The CAR-T cell therapy treatment market is segmented on the basis of the product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the CAR-T cell therapy treatment market is segmented into autologous CAR-T cells and allogeneic CAR-T cells. In 2021, autologous CAR-T cells segment is expected to dominate the CAR-T cell therapy treatment market because the drugs approved for CAR-T cell therapy are autologous in nature.
- On the basis of structure, the CAR-T cell therapy treatment market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells and fourth generation CAR-T cells. In 2021, second generation CAR-T cells segment is expected to dominate the CAR-T cell therapy treatment market because the approved therapies are second generation based structure.
- On the basis of targeted antigens, the CAR-T cell therapy treatment market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others. In 2021, antigens on hematologic malignancies segment is expected to dominate the CAR-T cell therapy treatment market because drugs approved for CAR-T cell therapy are majorly used for hematologic malignancies and ongoing extensive research development.
- On the basis of brand, the CAR-T cell therapy treatment market is segmented into yescarta, kymriah, tecartus and others. In 2021, yescarta segment is expected to dominate the CAR-T cell therapy treatment market because yescarta is the first approved CAR-T cell therapy for oncology therapeutic class.
- 치료적 적용을 기준으로 CAR-T 세포 치료 시장은 혈액 악성 종양, 췌장암 , 유방암, 폐암, 위암, 다발성 골수종, 만성 림프구성 백혈병 , 맨틀 세포 림프종, 모낭 림프종, 확산성 대형 B 세포 림프종, 급성 림프모구 백혈병 등으로 세분화됩니다. 2021년에는 혈액 악성 종양 부문이 CAR-T 세포 치료 시장을 지배할 것으로 예상되는데, 그 이유는 yescarta가 시장에서 주요 수익을 차지하고 모낭 림프종이 yescarta의 주요 적응증이기 때문입니다.
- 최종 사용자를 기준으로 CAR-T 세포 치료 시장은 병원 , 전문 클리닉 및 기타로 세분화됩니다. 2021년에는 병원 부문이 CAR-T 세포 치료 시장을 지배하고 있는데, 그 이유는 CAR-T 세포 치료가 첨단 기술 연구실을 갖춘 고도로 훈련된 전문가를 필요로 하기 때문입니다.
- 유통 채널을 기준으로 CAR-T 세포 치료 시장은 병원 약국 및 기타로 세분화됩니다. 2021년에는 병원 약국 부문이 CAR-T 세포 치료 치료 유통 채널을 지배할 것으로 예상됩니다. 병원 약국은 병원의 중심 부분이고 모든 주입 관련 및 약물 관련 배송은 약국 부서에서 판매되기 때문입니다.
CAR-T 세포 치료 치료 시장 국가 수준 분석
CAR-T 세포 치료 시장을 분석하고, 위에 언급된 국가, 제품, 구조, 표적 항원, 브랜드, 치료적 적용, 최종 사용자 및 유통 채널을 기반으로 시장 규모 정보를 제공합니다.
유럽 CAR-T 세포 치료 시장 보고서에서 다루는 국가는 독일, 영국, 프랑스, 이탈리아, 스페인, 네덜란드, 러시아, 스위스, 터키, 오스트리아, 노르웨이, 헝가리, 리투아니아, 아일랜드, 폴란드 및 기타 유럽 국가입니다.
독일의 자가 CAR-T 세포 분야는 암의 유병률로 인해 유럽 CAR-T 세포 치료 시장을 장악하고 있습니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 유럽 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
면역 요법에 대한 인지도 상승으로 CAR-T 세포 치료 시장 성장이 촉진되고 있습니다.
CAR-T 세포 치료 시장은 또한 CAR-T 세포 치료 산업의 모든 국가별 성장에 대한 자세한 시장 분석과 CAR-T 세포 치료 치료 판매, CAR-T 세포 치료 치료 기술 발전의 영향, CAR-T 세포 치료 치료 시장에 대한 지원과 함께 규제 시나리오의 변화를 제공합니다. 이 데이터는 2011년부터 2019년까지의 과거 기간에 대해 제공됩니다.
경쟁 환경 및 CAR-T 세포 치료 시장 점유율 분석
CAR-T 세포 요법 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선입니다. 제공된 위의 데이터 포인트는 CAR-T 세포 요법 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.
CAR-T 세포 치료제 시장 보고서를 다루는 주요 기업으로는 Autolus, Amgen Inc., bluebird bio, Inc., Adaptimmune Therapeutics plc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AbbVie Inc., Novartis AG, Kite Pharma(Gilead Sciences, Inc.의 자회사), Cellectis, TC BIOPHARM, Celyad Oncology 등이 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.
또한 전 세계 회사에서 많은 제품 출시와 계약을 체결하면서 CAR-T 세포 치료 시장도 가속화되고 있습니다.
예를 들어,
- 2020년 12월, Atara Biotherapeutics, Inc.는 고형 종양에 대한 메조텔린 표적 CAR T 세포 치료법 개발을 위해 Bayer AG와 협력을 시작했습니다. 계약에 따라, 이 회사는 악성 흉막 중피종과 비소세포 폐암을 치료하기 위해 ATA2271의 개발에 집중하고 있습니다. 이 협력을 통해 이 회사는 ATA2271에 대한 연구 개발을 가속화하고 선도적인 동종 CAR-T 세포 치료법 제조업체가 될 수 있었습니다.
협력, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 시장 참여자의 기타 전략은 CAR-T 세포 치료 시장에서 회사 시장을 강화하고 있으며, 이는 기업이 CAR-T 세포 치료에 대한 제공을 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
- introduction
- OBJECTIVES OF THE STUDY
- MARKET DEFINITION
- OVERVIEW of EUROPE CAR-T cell therapy treatment MARKET
- LIMITATIONs
- MARKETS COVERED
- MARKET SEGMENTATION
- MARKETS COVERED
- geographical scope
- years considered for the study
- currency and pricing
- DBMR TRIPOD DATA VALIDATION MODEL
- MULTIVARIATE MODELLING
- PRODUCT LIFELINE CURVE
- primary interviews with key opinion leaders
- DBMR MARKET POSITION GRID
- vendor share analysis
- MARKET product COVERAGE GRID
- secondary sourcEs
- assumptions
- EXECUTIVE SUMMARY
- premium insight
- Epidemiology
- Pipeline analysis
- Market Overview
- Drivers
- increase in usage of CAR-T CELL THERAPY for the treatment of cancer and infectious diseases
- increasing prevalEnce of cancer
- rise in awareness about immunotherapies
- increasing investment in research and development
- adoption of CAR-T cell therapy treatment in Emerging markets
- restraints
- adverse side effects of therapies
- high cost associated with therapies
- logistic challenge associated with CAR-T therapies
- availability of alternatives for tumor treatment
- opportunities
- presence of pipeline producTs
- strategiC initiatives by market players
- Rise in expenditure in healthcare sector
- challenges
- long approval time for immunotherapies
- lack of skilled professionals
- IMPACT OF COVID-19 ON EUROPE CAR-T CELL THERAPY TREATMENT MARKET
- IMPACT ON PRICE
- IMPACT ON DEMAND
- IMPACT ON SUPPLY CHAIN
- STRATEGIC DECISION FOR MANUFACTURERS
- CONCLUSION
- Europe CAR-T Cell Therapy Treatment MARKET, BY PRODUCT
- overview
- Autologous CAR-T Cells
- Allogeneic CAR-T Cells
- Europe CAR-T CELL THERAPY TREATMENT MARKET, BY Structure
- overview
- First Generation CAR-T Cells
- Second Generation CAR-T Cells
- Third Generation CAR-T Cells
- Fourth Generation CAR-T Cells
- Europe CAR-T CELL THERAPY TREATMENTMARKET, BY Targeted Antigens
- overview
- Antigens on Hematologic Malignancies
- Cluster of Differentiation-19 (CD-19)
- Cluster of Differentiation-30 (CD-30)
- Cluster of Differentiation-22 (CD-22)
- Cluster of Differentiation-20 (CD-20)
- Cluster of Differentiation-33 (CD-33)
- Antigens on Solid Tumors
- Human Epidermal Growth Factor Receptor-2 (HER-2)
- Epidermal Growth Factor Receptors Variant III (EGFRV-III)
- Mesothelin (MSLN)
- Prostate-Specific Membrane Antigen (PSMA)
- Interleukin-13RA2 (IL13RA2)
- Disialoganglioside 2 (GD2)
- Glypican-3 (GPC3)
- Others
- OTHERS
- Europe CAR-T cell therapy treatment MARKET, BY brand
- overview
- yescarta
- KYMRIAH
- TECARTUS
- others
- Europe CAR-T cell therapy treatment MARKET, BY therapeutic application
- overview
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma
- Acute Lymphoblastic Leukaemia (ALL)
- Mantle Cell Lymphoma
- Multiple Myeloma
- Hematologic Malignancies
- Leukemia
- Lymphoma
- Myeloma
- Others
- Lung Cancer
- Chronic Lymphocytic Leukemia
- Gastric Cancer
- Pancreatic Cancer
- Breast Cancer
- others
- Europe CAR-T cell therapy treatment MARKET, BY end user
- overview
- hospitals
- Specialty Clinics
- others
- Europe CAR-T cell therapy treatment MARKET, BY distribution channel
- overview
- hospital Pharmacy
- others
- Europe CAR-T cell therapy treatment market by geography
- EUROPE
- germany
- u.k
- France
- Italy
- Spain
- NETHERLANDS
- Russia
- Switzerland
- Belgium
- Turkey
- Austria
- Norway
- Hungary
- Lithuania
- Ireland
- Poland
- Rest of Europe
- Europe CAR-T Cell Therapy Treatment Market: COMPANY landscape
- company share analysis: europe
- swot analysis
- company profile
- kite pharma (A subsidiary of GILEAD SCIENCES, INC.)
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Novartis AG
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Abbvie inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Adaptimmune Therapeutics plc
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Amgen Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Atara Biotherapeutics, Inc.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- aurora biopharmA
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Autolus
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Bellicum Phamaceuticals, Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- BioAtla Inc.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- bluebird bio, inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Bristol-Myers Squibb Company
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- carina biotech
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cartherics pty ltd
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cartesian therapeutics, inc.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cellectis SA
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- celyad oncology SA
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Johnson & Johnson Services, Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- sorrento therapeutics, INC.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tc biopharm Limited
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tessa therapeutics ltd.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tmunity therapeutics
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- mustang bio
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Xyphos (A Subsidiary of Astellas Pharma Inc.)
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- ziopharm oncology, inc.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- questionnaire
- related reports
표 목록
TABLE 1 Europe CAR-T cell therapy treatment Market, pipeline analysis
TABLE 2 Below provided are the alternative chemotherapies of CAR-T cell therapy:
TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)
TABLE 4 Europe CAR-T CELL THERAPY TREATMENTMarket, By MOLECULE, 2019-2028 (USD Million)
TABLE 5 Europe Autologous CAR-T Cells in CAR-T CELL THERAPY TREATMENTMarket, By Region, 2017-2028 (USD Million)
TABLE 6 Europe Allogeneic CAR-T Cells in CAR-T CELL THERAPY TREATMENTMARKET, By Region, 2019-2028 (USD Million)
TABLE 7 Europe CAR-T CELL THERAPY TREATMENTMarket, By Structure, 2019-2028 (USD Million)
Celyad is engaged in the manufacturing of CYAD-211, a first generation CAR-T cell therapy expressing BCMA targeting chimeric antigen receptor which interferes with the expression of the CD3ζ of T cell receptor complex.
TABLE 8 Europe First Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 9 Europe Second Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 10 Europe Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 11 Europe Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 12 Europe CAR-T CELL THERAPY TREATMENTMarket, By targeted antigens, 2019-2028 (USD Million)
TABLE 13 Europe Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 14 Europe Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Hematologic Malignancies, 2019-2028 (USD Million)
TABLE 15 Europe Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)
TABLE 16 Europe Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Solid Tumors, 2019-2028 (USD Million)
TABLE 17 Europe others in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)
TABLE 18 Europe YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 19 Europe YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 20 Europe KYMRIAH in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 21 Europe TECARTUS in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 22 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 23 Europe CAR-T cell therapy treatment Market, By therapeutic type, 2019-2028 (USD Million)
TABLE 24 Europe Follicular Lymphoma in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)
TABLE 25 Europe Diffuse Large B-Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 26 Europe ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 27 Europe Mantle Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 28 Europe Multiple Myeloma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 29 Europe hematologic malignancies in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 30 Europe hematologic malignancies on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By therapeutic application, 2019-2028 (USD Million)
TABLE 31 Europe Lung Cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 32 Europe chronic lymphocytic leukemia in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 33 Europe gastric cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 34 Europe pancreatic cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 35 Europe breast cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 36 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 37 Europe CAR-T cell therapy treatment Market, By END USER, 2019-2028 (USD Million)
TABLE 38 Europe hospitals in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)
TABLE 39 Europe specialty clinics in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 40 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 41 Europe CAR-T cell therapy treatment Market, By distribution channel, 2019-2028 (USD Million)
TABLE 42 Europe hospital pharmacy in CAR-T cell therapy treatment Market, By distribution channel, 2017-2028 (USD Million)
TABLE 43 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 44 Europe CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)
TABLE 45 Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 46 Europe CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 47 Europe CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 48 europe Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 49 Europe Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 50 Europe CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 51 Europe CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 52 Europe Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 53 Europe CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 54 Europe CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 55 Germany CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 56 Germany CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 57 Germany CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 58 Germany Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 59 Germany Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 60 Germany CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 61 Germany CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 62 Germany Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 63 Germany CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 64 Germany CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 65 U.K CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 66 U.K CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 67 U.K CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 68 U.K Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 69 U.K Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 70 U.K CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 71 U.K CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 72 U.K Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 73 U.K CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 74 U.K CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 75 FRANCE CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 76 FRANCE CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 77 FRANCE CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 78 FRANCE Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 79 FRANCE Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 80 FRANCE CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 81 FRANCE CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 82 FRANCE Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 83 FRANCE CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 84 FRANCE CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 85 ITALY CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 86 ITALY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 87 ITALY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 88 ITALY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 89 ITALY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 90 ITALY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 91 ITALY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 92 ITALY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 93 ITALY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 94 ITALY CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 95 Spain CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 96 SPAIN CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 97 SPAIN CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 98 SPAIN Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 99 SPAIN Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 100 SPAIN CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 101 SPAIN CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 102 SPAIN Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 103 SPAIN CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 104 SPAIN CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 105 netherlands CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 106 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 107 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 108 NETHERLANDS Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 109 NETHERLANDS Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 110 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 111 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 112 NETHERLANDS Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 113 NETHERLANDS CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 114 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 115 Russia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 116 RUSSIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 117 RUSSIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 118 RUSSIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 119 RUSSIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 120 RUSSIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 121 RUSSIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 122 RUSSIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 123 RUSSIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 124 RUSSIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 125 Switzerland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 126 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 127 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 128 SWITZERLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 129 SWITZERLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 130 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 131 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 132 SWITZERLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 133 SWITZERLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 134 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 135 belgium CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 136 BELGIUM CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 137 BELGIUM CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 138 BELGIUM Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 139 BELGIUM Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 140 BELGIUM CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 141 BELGIUM CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 142 BELGIUM Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 143 BELGIUM CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 144 BELGIUM CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 145 turkey CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 146 TURKEY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 147 TURKEY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 148 TURKEY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 149 TURKEY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 150 TURKEY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 151 TURKEY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 152 TURKEY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 153 TURKEY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 154 turkey CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 155 Austria CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 156 AUSTRIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 157 AUSTRIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 158 AUSTRIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 159 AUSTRIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 160 AUSTRIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 161 AUSTRIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 162 AUSTRIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 163 AUSTRIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 164 Austria CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 165 norway CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 166 NORWAY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 167 NORWAY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 168 NORWAY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 169 NORWAY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 170 NORWAY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 171 NORWAY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 172 NORWAY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 173 NORWAY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 174 Norway CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 175 Hungary CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 176 HUNGARY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 177 HUNGARY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 178 HUNGARY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 179 HUNGARY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 180 HUNGARY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 181 HUNGARY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 182 HUNGARY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 183 HUNGARY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 184 Hungary CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 185 Lithuania CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 186 LITHUANIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 187 LITHUANIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 188 LITHUANIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 189 LITHUANIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 190 LITHUANIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 191 LITHUANIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 192 LITHUANIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 193 LITHUANIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 194 Lithuania CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 195 Ireland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 196 IRELAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 197 IRELAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 198 IRELAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 199 IRELAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 200 IRELAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 201 IRELAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 202 IRELAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 203 IRELAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 204 ireland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 205 Poland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 206 POLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 207 POLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 208 POLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 209 POLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 210 POLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 211 POLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 212 POLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 213 POLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 214 Poland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 215 Rest of Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
그림 목록
FIGURE 1 Europe CAR-T cell therapy treatment MARKET: SEGMENTATION
FIGURE 2 EUROPE CAR-T cell therapy treatment MARKET: DATA TRIANGULATION
FIGURE 3 Europe CAR-T cell therapy treatment Market: DROC ANALYSIS
FIGURE 4 Europe CAR-T cell therapy treatment market: Europe VS REGIONAL MARKET ANALYSIS
FIGURE 5 Europe CAR-T cell therapy treatment Market: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE CAR-T cell therapy treatment MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE CAR-T cell therapy treatment MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE CAR-T cell therapy treatment MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE CAR-T cell therapy treatment MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE car-t cell therapy treatment MARKET: MARKET product COVERAGE GRID
FIGURE 11 Europe car-t cell therapy treatment market: SEGMENTATION
FIGURE 12 increasing investment in research and development is expected to drive THE Europe CAR-T cell therapy treatment market IN THE FORECAST PERIOD OF 2021 to 2028
FIGURE 13 Autologus car-t cells SEGMENT is expected to account for the largest share of the Europe CAR-T CELL THERAPY TREATMENT market in 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGEs OF Europe CAR-T cell therapy treatment Market
FIGURE 15 New Cancer Cases Worldwide, (2018)
FIGURE 16 Europe Cancer Incidence (2018)
FIGURE 17 Cancer Death By Type (in million), world, 2017
FIGURE 18 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2021
FIGURE 19 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2019-2028 (USD Million)
FIGURE 20 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, CAGR (2021-2028)
FIGURE 21 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, LIFELINE CURVE
FIGURE 22 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2021
FIGURE 23 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2019-2028 (USD Million)
FIGURE 24 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, CAGR (2021-2028)
FIGURE 25 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, LIFELINE CURVE
FIGURE 26 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2021
FIGURE 27 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2019-2028 (USD Million)
FIGURE 28 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, CAGR (2021-2028)
FIGURE 29 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, LIFELINE CURVE
FIGURE 30 Europe CAR-T cell therapy treatment market: BY brand, 2020
FIGURE 31 Europe CAR-T cell therapy treatment market: BY brand, 2020-2028 (USD Million)
FIGURE 32 Europe CAR-T cell therapy treatment market: BY brand, CAGR (2020-2028)
FIGURE 33 Europe CAR-T cell therapy treatment market: BY brand, LIFELINE CURVE
FIGURE 34 Europe CAR-T cell therapy treatment market: BY therapeutic application, 2020
FIGURE 35 Europe CAR-T cell therapy treatment market: BY therapeutic application, 2020-2028 (USD Million)
FIGURE 36 Europe CAR-T cell therapy treatment market: BY therapeutic application, CAGR (2020-2028)
FIGURE 37 Europe CAR-T cell therapy treatment market: BY therapeutic application, LIFELINE CURVE
FIGURE 38 Europe CAR-T cell therapy treatment market: BY END USER, 2020
FIGURE 39 Europe CAR-T cell therapy treatment market: BY END USER, 2020-2028 (USD Million)
FIGURE 40 Europe CAR-T cell therapy treatment market: BY END USER, CAGR (2020-2028)
FIGURE 41 Europe CAR-T cell therapy treatment market: BY END USER, LIFELINE CURVE
FIGURE 42 Europe CAR-T cell therapy treatment market: BY distribution channel, 2020
FIGURE 43 Europe CAR-T cell therapy treatment market: BY distribution channel, 2020-2028 (USD Million)
FIGURE 44 Europe CAR-T cell therapy treatment market: BY distribution channel, CAGR (2020-2028)
FIGURE 45 Europe CAR-T cell therapy treatment market: BY distribution channel, LIFELINE CURVE
FIGURE 46 Europe CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)
FIGURE 47 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)
FIGURE 48 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)
FIGURE 49 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)
FIGURE 50 Europe CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)
FIGURE 51 EUROPE CAR-T Cell Therapy Treatment Market: company share 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
